CARY | CGMS | CARY / CGMS | |
Gain YTD | 6.819 | 6.541 | 104% |
Net Assets | 323M | 1.69B | 19% |
Total Expense Ratio | N/A | N/A | - |
Turnover | 59.43 | 43.00 | 138% |
Yield | 6.70 | 6.01 | 111% |
Fund Existence | 2 years | 2 years | - |
CARY | CGMS | |
---|---|---|
RSI ODDS (%) | 3 days ago90% | N/A |
Stochastic ODDS (%) | 3 days ago75% | 3 days ago48% |
Momentum ODDS (%) | N/A | 3 days ago77% |
MACD ODDS (%) | 3 days ago68% | 3 days ago79% |
TrendWeek ODDS (%) | 3 days ago6% | 3 days ago37% |
TrendMonth ODDS (%) | 3 days ago4% | 3 days ago29% |
Advances ODDS (%) | N/A | 10 days ago78% |
Declines ODDS (%) | 5 days ago5% | 3 days ago40% |
BollingerBands ODDS (%) | 3 days ago90% | 3 days ago44% |
Aroon ODDS (%) | N/A | 3 days ago27% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
CIBFX | 71.86 | -0.32 | -0.44% |
American Funds Capital Income Bldr F1 | |||
PILIX | 11.15 | -0.06 | -0.54% |
Principal International Equity Index R1 | |||
FAOAX | 31.93 | -0.41 | -1.27% |
Fidelity Advisor Overseas A | |||
CTYRX | 90.89 | -2.38 | -2.55% |
Columbia Global Technology Growth Adv | |||
RYCFX | 49.93 | -2.32 | -4.44% |
Rydex Biotechnology C |
A.I.dvisor tells us that CGMS and DBD have been poorly correlated (+12% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CGMS and DBD's prices will move in lockstep.
Ticker / NAME | Correlation To CGMS | 1D Price Change % | ||
---|---|---|---|---|
CGMS | 100% | -0.04% | ||
DBD - CGMS | 12% Poorly correlated | +3.76% |